The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

dc.contributor.authorde la Torre, Beatriz G.
dc.contributor.authorAlbericio Palomera, Fernando
dc.date.accessioned2020-05-06T15:36:26Z
dc.date.available2020-05-06T15:36:26Z
dc.date.issued2018-02-27
dc.date.updated2020-05-06T15:36:26Z
dc.description.abstractThis is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec680996
dc.identifier.issn1420-3049
dc.identifier.pmid29495494
dc.identifier.urihttps://hdl.handle.net/2445/158951
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/molecules23030533
dc.relation.ispartofMolecules, 2018, vol. 23, num. 3, p. 533
dc.relation.urihttps://doi.org/10.3390/molecules23030533
dc.rightscc-by (c) de la Torre, Beatriz G. et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)
dc.subject.classificationDisseny de medicaments
dc.subject.classificationPèptids
dc.subject.classificationFarmacologia
dc.subject.otherDrug design
dc.subject.otherPeptides
dc.subject.otherPharmacology
dc.titleThe Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
680996.pdf
Mida:
3.48 MB
Format:
Adobe Portable Document Format